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Abstract
At the time of their clinical manifestation, the heterogeneous group of adult and pediatric gliomas carries a wide range of
diverse somatic genomic alterations, ranging from somatic single-nucleotide variants to structural chromosomal rearrangements. Somatic abnormalities may have functional consequences, such as a decrease, increase or change in mRNA transcripts,
and cells pay a penalty for maintaining them. These abnormalities, therefore, must provide cells with a competitive advantage
to become engrained into the glioma genome. Here, we propose a model of gliomagenesis consisting of the following five
consecutive phases that glioma cells have traversed prior to clinical manifestation: (I) initial growth; (II) oncogene-induced
senescence; (III) stressed growth; (IV) replicative senescence/crisis; (V) immortal growth. We have integrated the findings
from a large number of studies in biology and (neuro)oncology and relate somatic alterations and other results discussed
in these papers to each of these five phases. Understanding the story that each glioma tells at presentation may ultimately
facilitate the design of novel, more effective therapeutic approaches.
Keywords Glioma · Gliomagenesis · Oncogenesis · Senescence · Telomerase

Introduction
Gliomas encompass a very diverse group and account for the
great majority of tumors originating in the parenchyma of
the central nervous system (CNS) [166]. Two larger glioma
groups are recognized: so-called diffuse gliomas, characterized by extensive infiltrative growth into the surrounding
CNS parenchyma, and more circumscribed (non-diffuse)
gliomas such as pilocytic astrocytoma and ependymomas. Diffuse gliomas, by far the most frequent gliomas in
adult patients, are traditionally classified according to their
microscopic similarities with (precursors of) glial cells and
then designated as diffuse astrocytomas, oligodendrogliomas or mixed gliomas/oligoastrocytomas. Additionally,
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a malignancy grade is assigned to these tumors based on
the presence/absence of especially marked mitotic activity, florid microvascular proliferation (MVP), and necrosis
[175, 233]. For over a century, such microscopic evaluation
has provided the gold standard for the diagnosis of gliomas,
assessment of prognosis and formed the basis for therapeutic management. However, multiple studies showed that a
purely histopathologic classification suffers from considerable inter- and intraobserver variability [3, 46, 217].
As with other human cancers, the pathogenesis and
molecular evolution of gliomas are often characterized
by somatic chromosomal aberrations, widespread or focal
copy number changes and targeted gain and loss of function events in oncogenes and tumor suppressor genes [211,
224, 225]. Various permutations of somatic alterations
were shown to be associated with distinct tumor entities
and differential sensitivities to treatment, such as a chromosome 1p/19q-codeletion in oligodendrogliomas conferring
increased sensitivity to chemotherapy [26, 27]. In the course
of the last two decades, it became increasingly clear that
such molecular characteristics may provide a more robust
and objective basis for subtyping of diffuse gliomas and both
scientists and clinicians turned towards molecular markers
to aid diagnosis [30, 34, 59, 234, 244]. Indeed, the International Society for Neuropathology—Haarlem Consensus
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Guidelines and the most recent edition of the WHO classification of CNS tumors (published in 2016) embraced the
notion of an integrated histo-molecular classification of diffuse gliomas [130, 131].
In adult patients three major subgroups of diffuse glioma
are now defined based on the presence or absence of mutations in the isocitrate dehydrogenase 1 (IDH1) or IDH2 gene
and of complete, combined loss of the short arm of chromosome 1 and of the long arm of chromosome 19 (complete
1p/19q-codeletion):
• IDH-wildtype: most of these histologically represent

astrocytic tumors, a large percentage belonging to the
highest malignancy grade, i.e., glioblastomas.
• IDH-mutant and 1p/19q-non-codeleted: these tumors
also generally have an astrocytic phenotype, but a much
larger percentage is at first diagnosis histologically lower
grade/WHO grade II or III.
• IDH-mutant and 1p/19-codeleted: most of these are characterized by a prominent oligodendroglial phenotype of
the tumor cells.
Following this strategy, the diagnosis of mixed glioma/
oligoastrocytoma can be expected to largely disappear,
except when additional molecular tests cannot be performed
or do not provide unequivocal results; in that situation, nototherwise-specified (NOS) should be added to the diagnosis
to indicate that ideally such samples require further workup
[132]. Rare ‘dual genotype’ oligoastrocytomas have been
reported that show polymorphic phenotypes with both a
complete 1p/19q-codeletion component and non-codeleted
component [93, 235]. Diffuse midline glioma, H3 K27Mmutant, was added in the WHO 2016 classification as a
separate entity [116, 191, 242]. This type of diffuse glioma,
which most often occurs in children, is by definition located
in the ‘midline’ of the CNS (brainstem, thalamus, cerebellum and/or spinal cord) and considered as highly aggressive (WHO grade IV) irrespective of the malignancy grade
assigned by histology [129]. By far, the most frequent astrocytic tumors in children though are pilocytic astrocytomas
that generally are more circumscribed (therefore, grouped
under non-diffuse gliomas) and show an indolent, WHO
grade I behavior [44, 105, 190]. Meanwhile, the transition
from a purely histological to a histo-molecular classification of especially diffuse gliomas represents a paradigm shift
and necessitates re-evaluation of histologic criteria used for
grading and guidance of therapeutic decisions [164, 181].
In this review, we summarize current knowledge and propose five phases in gliomagenesis that occur sequentially
and ultimately lead to its clinical manifestation (Fig. 1).
Each phase is characterized by distinct molecular alterations and phenotypic characteristics, such as differences in
growth dynamics and evolutionary mechanisms. A critical

13

Acta Neuropathologica (2018) 135:649–670

assumption in our model is the existence of two growth barriers, which we refer to as oncogene-induced and replicative
senescence. Similar barriers have been described in detail
in the context of cultured epithelial cells and fibroblasts and
much of this work has paved the road for our understanding of these mechanisms in gliomagenesis [77, 183, 239].
In the model we propose, the first phase of initial growth
(phase I) follows the acquisition of a glioma initiation event
and is characterized by aberrant proliferation of pre-tumor
cells. Continued oncogenic exposure may impede tumor
growth and trigger a durable form of cell cycle arrest termed
oncogene-induced senescence (phase II) in a majority of
tumor cells. Some phase I/II cells may acquire molecular
changes to bypass oncogene-induced senescence and continue growth in spite of unfavorable and stressful conditions
including DNA damage and dysfunctional telomeres. Continued growth despite incremental genomic instability marks
the third phase of stressed growth (phase III). This second
round of glioma cell growth under harsh conditions triggers
a second round of durable growth arrest termed replicative
senescence (phase IV) and in some cases, brings forth a state
of cellular crisis characterized by widespread cell death.
Rare cells may acquire stem-like characteristics and a means
to continue growth indefinitely, giving rise to a final phase of
immortal growth (phase V). Such phase V glioma stem-like
cells uphold the tumor progenitor cell population via their
capacity for self-renewal and may also give rise to more differentiated and growth-arrested stage IV cells, losing their
stem-like properties. In this manuscript, we systematically
review the evidence for this model and propose candidate
mechanisms where definitive evidence is lacking. Acknowledging that this model is an abstract simplification of gliomagenesis, we also provide some examples of exceptions and
conflicting evidence. While the focus of this review is on
various molecular categories of diffuse glioma recognized
by the most recent WHO classification, a few examples in
the realm of non-diffuse gliomas are touched upon as well.

A model for the temporal molecular
pathogenesis of gliomas
Phase I: initial growth
The theory that cancer results from accumulation of mutations over time, in a subset of patients combined with contribution of inherited risk factors, has been around for over six
decades and has been refined over the years [5, 79, 80, 111,
158, 160]. For the purpose of this review we will consider
a glioma initiation event to be the first acquired (somatic)
event towards developing glioma. This event should provide
a competitive growth advantage, either by directly increasing
proliferation or by creating the conditions in which increased
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Fig. 1  Model of the molecular life history of gliomas, prior to becoming clinically manifest. The temporal sequence of events can be subdivided into five phases (I–V) represented in different colors. a The
number of dividing cells (or proliferation rate) across each phase.
Proliferation peaks towards the end of growth phases and dips going
into senescence phases. b The tumor mass across each phase. Tumor
mass increases exponentially during growth phases and logarithmically during senescence phases. c Telomere length across each phase.
Telomere length over time follows a pattern that is inverse to tumor
mass. d Cell doubling diagram indicating the growth barriers (senes-
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cence phases) and resulting selection bottleneck. e Somatic alterations associated with different phases in gliomagenesis. The timing of
each event is indicated on the x-axis of panel C. Genomic instability
events are accumulated during phase III–IV. Of note, this model is
a simplified representation of true gliomagenesis. The x-axis is not
drawn to scale, in part because the duration of the phases likely varies
from cell to cell and between various tumor types. Furthermore, the
position of the curves is arbitrary as cells in a tumor may not be in
sync. BFB breakage–fusion–bridge, DM double minute, ALT alternative lengthening of telomeres
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proliferation may happen. Cells and their progeny characterized by such an event will be primed to outcompete neighboring cells giving rise to an initial submicroscopic tumor
mass. While germline events that contribute to glioma risk
precede such glioma initiation events, their incomplete penetrance suggests that they cannot be considered as causal
for glioma formation and instead prime the environment for
tumor formation [196]. Furthermore, even if a glioma initiation event marks the first somatic event in the formation of a
tumor it may not be responsible for initiating growth directly.
Instead, this event may promote tumorigenesis indirectly via
stochastic activation of oncogenes or repression of tumor
suppressors. Genetic or epigenetic selection pressures will
prioritize daughter cells with growth advantages over those
without and daughter cells with lethal genotypes will rapidly
disappear [64, 150, 245].
IDH‑mutant diffuse gliomas
Mutations in IDH1/IDH2 are commonly considered to be
glioma initiating. Several studies have shown that they are
amongst the few alterations highly shared amongst gliomas
at first presentation and their recurrences [9, 100, 204] which
is explained by their presence in the cell of origin and all
cells derived thereof. Comparing multiple biopsies from the
same tumor, IDH mutation can be confidently detected in
each tumor segment and thus fit the proposed criteria of a
glioma initiation event [107, 124, 204]. In vitro experiments
have demonstrated that IDH mutations alone are sufficient to
reprogram the transcriptome and epigenome of normal cells
to prevent these cells from entering a terminally differentiated state [134, 147, 213].
IDH dysregulation likely contributes to gliomagenesis
via the accumulation of the oncogenic metabolite R(−)-2hydroxyglutarate (2HG) [114, 176]. Wildtype IDH enzymatically converts isocitrate into α-ketoglutarate (α-KG) as part
of the citric acid cycle, whereas mutant IDH metabolizes
α-KG into 2HG [54, 231]. Both mutant and wildtype IDH
alleles are, therefore, essential for the oncogenic function of
IDH. IDH mutations in glioma result in genome-wide hypermethylation [159, 213], most likely due to effects of 2HG
on the ten–eleven translocation methylcytosine dioxygenase
(Tet) family of proteins [61, 134, 243]. This hypermethylation may provide a growth advantage to cancer cells due to
the epigenetic activation of oncogenes via stochastic activation of alternative gene regulatory programs, some conferring added fitness [64]. One such mechanism in glioma may
be through methylation-induced disruption of a CCCTCbinding factor (CTCF) binding site, resulting in aberrant
activation of platelet-derived growth factor receptor alpha
(PDGRFA) [63].
Although most experimental models of IDH involve overexpression of mutant IDH in vitro, several transgenic mouse
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models have been described [28, 125]. Early transgenic
models showed that conditional knock-in of mutant IDH in
the murine brain led to perinatal lethality [188]. A more
recent inducible model demonstrated that mutant IDH led
to increased proliferation and infiltration in the CNS parenchyma of murine neural stem cells [10]. Though these mice
eventually died due to hydrocephalus and did not develop
malignant tumors, they showed symptoms of the initial
phases of gliomagenesis. Thus, while experimental models
of mutant IDH are generally insufficient to cause glioma,
mutant IDH leads to changes that could be interpreted as
early tumor development.
IDH‑wildtype diffuse astrocytomas
Approximately 70% of IDH-wildtype diffuse astrocytomas
are characterized at the molecular level by a single copy loss
of chromosome 10 and gain of chromosome 7 (+ 7/− 10)
[16, 34]. Loss or diploid loss of heterozygosity of chromosome 10 and of chromosome arm 10p in particular has been
reported to occur more frequently and may precede gain of
chromosome 7 [94]. Based on evolutionary modeling using
primary-recurrent tumor pairs and multisector tumor sampling, several independent groups have found that + 7/− 10
is homogeneous and longitudinally preserved and thus likely
the first and glioma initiation event in a large fraction of
IDH-wildtype diffuse astrocytomas/glioblastomas [69, 107,
168, 198, 229]. A recent study suggested that gains of chromosome 7 likely occur early in tumorigenesis, amongst the
first 10% of driver events [69]. In the past several years,
there has been a lot of interest in the role of TERT promoter
mutations in oncogenesis and an increasing body of evidence suggests that these mutations precede + 7/− 10 [106].
Nevertheless, a potential role of TERT promoter mutations
to promote proliferation in the initial growth phase and as a
glioma initiation event is speculative and will be discussed
later in this review.
Chromosome 7 is home to several oncogenes that have
been implicated in gliomagenesis such as cyclin-dependent
kinase 6 (CDK6), MET proto-oncogene (MET) and epidermal growth factor receptor (EGFR), while chromosome 10
hosts several tumor suppressor genes, including Tet family
member Tet methylcytosine dioxygenase 1 (TET1) and phosphatase and tensin homolog (PTEN). Though these genes
comprise the prime suspects, it is unlikely that they alone are
responsible for initiating glioma development [168]. Studies
across different diseases and in various model organisms
have shown that large chromosomal copy number changes
led to gross gene dosage fluctuations impacting various specific and general cellular functions [206]. Such changes may,
therefore, act in concert to promote tumor development.
Some IDH-wildtype diffuse gliomas show cytogenetically
intact chromosomes 7 and 10, implying that other initiation
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events give rise to these tumors as well. Such events may
include activating or inactivating alterations in the phosphoinositide 3-kinase (PI3K), receptor tyrosine kinase (RTK)
and mitogen-activated protein kinase (MAPK) pathways
[142]. PI3K pathway alterations include mutations in PI3kinase subunit alpha (PIK3CA), PI3-kinase subunit P85alpha (PIK3R1), or inactivation the aforementioned tumor
suppressor PTEN [127, 173, 199]. Glioma initiation events
may also include point mutations in RTK pathway genes
such as EGFR and PDGFRA or in MAPK pathway genes
such as neurofibromin 1 (NF1) [220]. Much is already
known about the effect of these mutations on cancer growth
but additional research is needed to secure their potential
role as glioma initiation events.
A particular subgroup of diffuse IDH-wildtype gliomas
is characterized by mutations in H3 histone family members and these gliomas occur most often in children [191,
202, 241]. The diffuse midline glioma, H3 K27M-mutant,
shows a lysine to methionine substitution at position 27
of the H3 histone family member 3A (H3F3A) or histone
cluster 1 H3 family member 3B (HIST1H3B) gene and is
included in the WHO 2016 classification as a separate entity.
Other H3-mutant diffuse gliomas in children and adolescents
occurring predominantly in the cerebral hemispheres often
show H3 G34R/V mutation (implying a glycine 34 to arginine or valine substitution) [115, 201, 202, 241]. In contrast
to hypermethylated IDH-mutant gliomas, these H3-mutant
gliomas have a general DNA hypomethylation phenotype
[14]. A recent study showed that expression of mutant H3
K27M in neonatal mice brains led to ectopic proliferation,
indicating a possible pre-cancerous change [126]. Although
additional support is needed, combined with their apparent
mutual exclusivity with mutations in IDH and changes characteristic for IDH-wildtype tumors, these findings indicate
that H3 K27M and H3 G34R/V mutations may be glioma
initiation events [32].
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contribute to tumorigenesis by constitutively activating the
kinase domain of BRAF, resulting in overactive signaling
activity and a selective growth advantage for affected cells
[55, 67, 102]. In most pilocytic astrocytomas (even after
thorough analysis), an activating change in BRAF or other
MAPK pathway members is the only genomic change that
can be confidently detected, implying that it is the glioma
initiation event in this disease [187].

Phase II: oncogene‑induced senescence
Continued oncogenic signaling in the initial growth phase
prompts the activation of tumor suppressive signaling via
activation of the p 16INK4a/p14ARF–RB–p53 cell cycle and
cell stress pathways (Fig. 2), slowing tumor growth and
transitioning a majority of cells with intact pathways into
a terminal state called oncogene-induced senescence [43].
First discovered over five decades ago in cultured fibroblasts,
senescence is a stress-induced durable cell cycle arrest [82].
The role of senescence in cancer has been reviewed extensively [29, 42, 78, 83, 174, 193]. Briefly, senescence provides a major tumor suppressive barrier and dividing tumor
cells are put under selection pressure to acquire molecular events to prevent or overcome its onset. Hallmarks of
senescence include durable growth arrest; short, dysfunctional telomeres; and a marked increase in DNA damage and
stress signaling [42]. Although senescent cells are growth
arrested, they are metabolically active and release a plethora
of signaling molecules to the microenvironment, also known
as the senescence-associated secretory phenotype [174].

Non‑diffuse gliomas
Recent studies have shown that pilocytic astrocytomas near
universally harbor abnormalities in the MAPK pathway, and
most commonly a tandem duplication targeting chromosome
7q, which gives rise to a KIAA1549–BRAF fusion gene
consisting of the N terminus of KIAA1549 and the kinase
domain of v-RAF murine sarcoma viral oncogene homolog
B1 (BRAF) [44]. Alternative alterations include the oncogenic V600E missense mutation also targeting BRAF [190].
The BRAF V600E mutation results in an activating change
due to a substitution of valine with glutamic acid at codon
600. In a non-cancer setting, BRAF activates kinases MEK
and ERK, which in turn activate transcriptional machinery to
promote differentiation, proliferation, growth and apoptosis
[31]. Both BRAF V600E mutation and BRAF fusion genes

Fig. 2  Process diagram indicating the 
p16INK4a/p14ARF–RB–p53
pathway in normal conditions. Disruption of one or multiple components through mutation or copy number change may prevent or suppress the onset of senescence. Various stimuli use different routes to
activate the senescence response, leaving compensatory mechanisms
in place in case components fail. For example, if oncogene-induced
senescence is repressed via CDKN2A/B inactivation, DNA damage
and telomere shortening could still trigger replicative senescence via
ATM and ATR. CDKs cyclin-dependent kinases (e.g., CDK2), MDMs
murine double minutes (e.g., MDM2)
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Distinction must be made between oncogene-induced senescence which is discussed here and is triggered by chronic
oncogenic signaling, and replicative senescence discussed
later, describing senescence triggered by telomere dysfunction following extensive replicative cycles [193]. Oncogeneinduced senescence poses a significant growth barrier and
most cells will not acquire molecular alterations that allow
them to bypass this barrier and will, therefore, become
senescent [43]. However, rare cells may acquire such alterations, eliciting a selective sweep by a subclone that will
rapidly dominate the neoplastic cell population.
In some cancer types, a senescent precursor stadium
can be identified, such as intestinal polyps in colon cancer
and dysplastic naevi in melanoma [192]. In contrast to the
catastrophic karyotypes demonstrated by their later stage
derivatives, these growth-arrested senescent precursor
lesions entered a senescent state via the activation of single
oncogene such as BRAF and are otherwise genetically unremarkable [72, 117, 151, 153]. This begs the question if such
premalignant precursor changes exist for diffuse gliomas as
well. If so, such precursor lesions may, however, well be
(sub)microscopic in size and go unnoticed in imaging or
autopsy studies.
The tumor suppressor proteins p16INK4a, p14ARF, RB
and p53 can be considered as gatekeepers of senescence.
The INK4a/ARF locus on chromosome 9 contains both
cyclin dependent kinase inhibitor 2A (CDKN2A) and 2B
(CDKN2B), combined encoding for both p 16 INK4a and
p14ARF via alternative splicing. Tumor suppressors RB and
p53 on the other hand are encoded for by the genes retinoblastoma 1 (RB1) and tumor protein 53 (TP53) on chromosomes 13 and 17, respectively. Inactivation of one or multiple of these genes via genomic deletion and/or inactivating
mutations has been linked to repression of senescence signaling and is a common event in all cancers including gliomas [39, 83, 195, 240]. For the purpose of this review, we
define the term ‘senescence bypass event’ as any molecular
alteration that suppresses the onset of oncogene-induced
senescence.
IDH‑mutant diffuse astrocytomas
IDH-mutant astrocytomas are often characterized by loss of
one allele of TP53, combined with a loss-of-function mutation in the remaining allele. The frequency of TP53 mutations in IDH-mutant (‘secondary’) glioblastomas is comparable to that in lower grade IDH-mutant astrocytomas from
which these glioblastomas are derived via malignant progression, suggesting that TP53 aberrations are early lesions
in these tumors [162]. Furthermore, and in contrast to IDHwildtype gliomas, TP53 mutations were shared between all
TP53-mutant cases of primary and recurrent tumors in a
recent study [100]. Analysis of multiple biopsies from the
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same IDH-mutant tumors indicated that samples mutant for
TP53 were always IDH mutant, while some IDH-mutant
samples lacked TP53 mutations, suggesting that IDH mutations precede TP53 inactivation [232]. IDH mutation and
TP53 inactivation, therefore, both comprise early events in
gliomagenesis, with TP53 inactivation generally following
mutation in IDH.
The p53 tumor suppressor protein is involved in many
different functions, and especially its role in cell cycle
arrest and senescence is very well understood [81]. While
enzymatically active wildtype p53 triggers senescence in
response to oncogenic stress, mutant p53 inadequately
blocks proliferation thereby bypassing the onset of oncogene-induced senescence. In addition, p53 takes a prominent role in the senescence pathway (Fig. 2) and loss of its
enzymatic activity impacts replicative senescence, triggering
crisis [195]. This is discussed further in phase IV (“Phase
IV: Replicative senescence/crisis” section).
IDH‑mutant oligodendrogliomas, 1p/19q‑codeleted
The majority of IDH-mutant tumors wildtype for TP53
demonstrate a combined single copy loss of the complete
chromosome arms 1p and 19q (complete 1p/19q-codeletion)
[20, 27]. These tumors are the canonical oligodendrogliomas according to the revised WHO criteria [130]. Though
it has been suggested that 1p/19q-codeletions are the result
of an unbalanced translocation, much about the contribution
of this event to oncogenesis remains to be resolved [95].
1p/19q-codeletion was found to be stable across longitudinal samples and multiple biopsies, suggesting that they are
early events [1, 97, 218]. The finding that codeleted tumors
are almost exclusively IDH-mutant, while the reverse is
not true, suggests that mutations in IDH precede codeletion. This suggestion may implicate a common cell of origin for both astrocytoma (IDH-mutant, non-codeleted) and
oligodendroglioma (IDH-mutant and 1p/19q-codeleted).
Indeed, recent evidence was provided that substantiates this
hypothesis, demonstrating that differences in inferred cell
identity between oligodendrogliomas and astrocytomas may
be entirely explained by different microenvironment makeup
and the impact of the 1p/19q-codeletion on the expression
of genes on these chromosome arms [219]. The authors
found that although these histological tumor types differ in
morphology, these histological subtypes share a comparable developmental hierarchy and glial lineage. Transcription factors involved in oligodendrocyte differentiation are
also expressed in both histologies [6]. Several case reports
have highlighted ‘dual genotype’ oligoastrocytomas, demonstrating molecular features of both bona fide astrocytic
and bona fide oligodendroglial tumor cells [93, 235]. Such a
dual genotype may be explained by assuming that very early
in gliomagenesis a subset of IDH-mutant cells experiences

Acta Neuropathologica (2018) 135:649–670

a complete 1p/19q-codeletion and a TERT promoter mutation, while another IDH-mutant subset acquires a mutation
in TP53 and/or ATRX. Detailed and sufficiently powered
longitudinal studies of primary and recurrent diffuse gliomas may help to elucidate the actual frequency of such
‘dual genotypes’, how they are related to mixed histological
appearances, and how they evolve over time [2].
Additional loss-of-function mutations in far-upstream
element binding protein (FUBP1) on 1p31.1 and capicua
transcriptional repressor (CIC) on 19q13.2 are observed in
over 60% of 1p/19q-codeleted gliomas [15]. A paired analysis of primary and recurrent 1p/19q-codeleted oligodendrogliomas described distinct alterations in CIC and FUBP1
in the primary and the recurrent tumor [9]. Another report
described that these events were frequently private to either
primary or recurrence, but not both [1]. Both findings corroborate observations of CIC and FUBP1 mutation heterogeneity across nine distinct samples from the same oligodendroglioma, including finding five distinct CIC mutants
across nine tumor samples [204]. Loss-of-function mutations in these genes led to a loss of protein expression and
the FUBP1 mutation was associated with adverse survival
compared to wildtype tumors [35, 90]. These findings suggest an important role for these genes and indicate that in
cases in which these events were not found in one sample
of the tumor, they still might be present elsewhere. Despite
their apparent importance, the role of these events in gliomagenesis remains to be understood.
It is not clear whether 1p/19q-codeleted oligodendrogliomas undergo senescence or acquire mechanisms to bypass
senescence. 1p/19q-codeleted gliomas generally lack alterations in genes associated with oncogene-induced senescence
such as BRAF or senescence bypass such as TP53, RB1
or CDKN2A. Nevertheless, given their continued clinical
growth it appears that these tumors have somehow evaded
growth arrest and senescence barriers. Perhaps the 1p/19qcodeletion allows pre-cancerous cells to avoid senescence
through the mono-allelic inactivation of tumor suppressor
genes on these chromosome arms [197]. One mechanism
that was previously proposed may be via a dosage-dependent
repression of chromodomain helicase DNA-binding domain
5 (CHD5) on 1p36 [7, 8, 222]. A study that used genetic
engineering to create mouse models with gains and losses of
a region corresponding to human 1p36 found that duplication of this region led to decreased proliferation and senescence whereas a single-copy deletion led to immortalization
[8].
IDH‑wildtype diffuse astrocytomas
Amongst IDH-wildtype astrocytomas/glioblastomas, one
of the most frequent alterations is a homozygous loss of
CDKN2A and CDKN2B [128]. Mathematical modeling has
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suggested that homozygous CDKN2A/B loss occurs after
+7/−10 but before other molecular events [168]. Homozygous CDKN2A/B loss alone is insufficient for tumor formation in mice, requiring the activation of an oncogene
to generate tumors in vivo [215]. As such, homozygous
CDKN2A/B loss is likely a second event in the tumorigenesis of IDH-wildtype astrocytoma or glioblastoma. The role
of protein products p16INK4a and p14ARF in senescence is
very well understood. Indeed, astrocytes with a homozygous
deletion of CDKN2A/B can grow indefinitely in culture, and
introduction of p 16INK4a in immortal human glioma cell lines
with this deletion leads to cell cycle arrest and senescence
[87, 216]. Taken together, these results indicate that loss of
CDKN2A/B may provide adult IDH-wildtype astrocytomas
with a reliable means for senescence bypass.
Mutations in TP53 sometimes co-occur with homozygous CDKN2A/B loss in IDH-wildtype glioma [163]. While
TP53 mutations are often shared across all tumor cells in
IDH-mutant astrocytoma, TP53 mutations in IDH-wildtype
astrocytomas are frequently unique to one or a few tumor
subclones [107]. In this same study, it was found that
amongst IDH-wildtype astrocytomas, whereas CDKN2A/B
is consistently deleted, TP53 mutations are frequently lost or
gained at tumor recurrence. These observations suggest that,
in IDH-wildtype astrocytoma, CDKN2A/B may be primarily
important for senescence regulation
Pediatric H3-mutant/IDH-wildtype diffuse gliomas are
TP53 mutant in about 50% of cases, which may act as a
senescence bypass event in these tumors [191]. Amongst
remaining H3-mutant tumors, approximately 20–30% of H3
K27 mutant diffuse gliomas show mutations in Activin A
Receptor Type 1 (ACVR1) [23, 65, 208, 242]. There is no
evidence that ACVR1 has any role in sentence regulation;
however, ACVR1 alterations were found to be mostly mutually exclusive with alterations in TP53 and PPM1D. PPM1D
is a protein phosphatase downstream of p53 involved in
apoptosis regulation following DNA damage and thus likely
involved in senescence [62]. Expression of ACVR1 mutants
in Tp53null murine astrocytes implanted in mouse brains
failed to induce tumors, likely because H3 K27 mutations
are required as a tumor initiation event and thus suggesting
that ACVR1 does not meet the criteria for a tumor initiation
event [242]. Thus, while about half of pediatric H3-mutant
gliomas demonstrate TP53 mutations that may act to bypass
senescence, it remains unclear if and how TP53-wildtype
H3-mutant pediatric gliomas bypass senescence.
Non‑diffuse gliomas
Several lines of evidence suggest that pilocytic astrocytomas (WHO grade I, IDH-wildtype) are arrested in a senescent phase II state and do not advance to later phases. First,
these tumors were found to frequently demonstrate several
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biomarkers of senescence at tumor detection, including
widespread β-galactosidase activity and p16INK4a staining [88, 112, 177]. Second, these tumors are very quiescent genetically, often demonstrating but a single activated
oncogene, such as a BRAF fusion, BRAF V600E mutation
or rarely an activating mutation in FGFR1 or PTPN11 [101,
212, 246]. Third, these tumors generally grow slowly, have
excellent outcomes and sometimes regress, perhaps because
the tumor cells do not immortalize [24, 25, 75, 185]. Fourth,
expression of activated BRAF V600E alone does not lead
to tumor development in in vitro and in in vivo mouse
models, while the combined activation of BRAF and loss
of CDKN2A/B is transforming, suggesting that additional
mutations to bypass senescence are required to advance to
phase III [92, 182, 189]. The clinical presentation of pilocytic astrocytoma may be the result of senescence-mitigating
circumstances, such as a cell of origin with proliferative
potential in the absence of senescence-bypass.

Phase III: stressed growth
Cells presenting with continued proliferative signaling
beyond the oncogene-induced senescence barrier are generally characterized by defective DNA damage response signaling and continued growth in a stressed environment. During this phase the repetitive DNA at the telomeric terminal
ends of chromosomes become increasingly important [161].
Telomeres progressively shorten as cells divide due to the
linear conformation of chromosomes and directional replication machinery, a phenomenon that is critically important
for diseases like cancer which are characterized by often
rampant proliferation [165]. Telomeric DNA takes on a lasso
conformation called the t-loop, and these loops are bound
by the shelterin DNA-binding protein complex. Together,
these characteristics protect chromosome ends from being
recognized as DNA double-strand breaks and prevent inadvertent activation of DNA damage response pathways [56].
Dysfunctional telomeres are critically short and improperly protected telomeres lacking t-loops and shelterin complexes. They trigger the activation of DNA damage response
pathways via ataxia telangiectasia-mutated (ATM) and ataxia
telangiectasia and Rad3-related (ATR) kinase, which are
triggered by exposed and unprotected double-stranded and
single-stranded DNA break ends, respectively. The exposed
ends then fall victim to homology directed repair (HDR)
and non-homologous end joining (NHEJ) repair processes,
intended to repair accidental DNA breaks but lead to gross
genomic instability when triggered by dysfunctional telomeres. When telomeres are unprotected, these repair processes
prompt sister chromatids to fuse with one another, forming
a dicentric chromosome. During the anaphase, the dicentric chromosome will form a bridge spanning the mitotic
spindle and connecting the two daughter cells. Resolution
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of the chromatin bridge via cytoplasmic 3′ nuclease TREX1
results in breakage of the dicentric chromosome at a locus
not necessarily at the site where the fusion had occurred,
resulting in an unbalanced inheritance of genetic material between the two daughter cells. Because the resulting
daughter cells also lack telomeres, this process of breakage–fusion–bridge (BFB) cycles (Fig. 3a) will repeat itself
every subsequent cell division until telomeres are restored
[4, 70, 144, 148, 149]. The detrimental genomic instability
acquired via telomere dysfunction and BFB cycles endows
these cells with powerful stochastic mutational mechanisms
to acquire changes that provide a survival benefit under
selective pressure.
The intensity of genomic instability endured during
the stressed growth phase may depend on the severity of
senescence pathway dysregulation incurred overcoming oncogene-induced senescence (Fig. 2). In the case of
H3-mutant, IDH-wildtype and IDH-mutant astrocytoma/
glioblastoma this pathway is perturbed close to the source
via the direct loss of RB, p53 or p16INK4a protein function.
In IDH-mutant and 1p/19q-codeleted oligodendroglioma
this pathway may be repressed indirectly, for example, via
the modulation of p14ARF activity through a partial deletion
of CHD5. This may explain why the latter group of tumors
shows significantly less genomic instability compared to the
former tumor types. Moreover, in pilocytic astrocytoma this
pathway may not be affected at all and these tumors may
not advance beyond oncogene-induced senescence. While
genomic instability incurred during phase III demonstrates
some patterns that are unique to a certain glioma subtype,
these features are generally shared across all gliomas regardless of subtype. We, therefore, did not separate this section
according to tumor type as we did for the other phases. More
research is needed to carefully delineate the selective pressures at play to better understand differences and similarities
between various glioma entities in this respect.
The advent of high-throughput sequencing has led to
remarkable progress in understanding the complexity of
genomic instability in cancer, including complex deletions,
amplifications and translocations [245]. It is important to
note that the genomic organization that can be reconstructed
using sequencing at the time of analysis are those changes
that resulted in viable cells and were selected for. Recent
work has shown that telomere dysfunction directly leads to
catastrophic genomic events, including genome shattering
(chromothripsis), clustered regions of focal hypermutation
(kataegis) and whole genome doubling (tetraploidization)
[60, 137, 138]. Although the incidence of chromothripsis
across the spectrum of gliomas is not known, a recent report
suggests that chromothripsis is very common in glioblastoma [139]. Comparison of primary and recurrent tumors
across various tumor types including gliomas demonstrated
that recurrent tumors lack additional genomic instability,
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Fig. 3  Genomic instability related to telomere stress. a Schematic
illustrating BFB cycles. Following a single BFB cycle, daughter cells
are left with unequal DNA content, leading to a deletion in A and an
amplification in B. BFB cycles may also involve fusion of non-sister
telomeres (not shown). b Repetitive BFB cycles form palindromes
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demonstrating high intra-segmental homology. This can lead to intrachromosomal fusions and formation of double minutes. c Following
chromothripsis segments can be rearranged, lost or circularized. TSG
tumor suppressor gene, OG oncogene, DDR DNA damage response,
DM double minutes, BFB breakage–fusion–bridge
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suggesting that these events occurred during a stressful
period, the initial development of the tumor that was later
stabilized [60].
Recently, there has been a renewed interest in circular
extrachromosomal DNA elements called double minute
(DM) chromosomes in cancer, and it was shown that such
DMs are common in gliomas [57, 214]. Although DM chromosomes have been long recognized as a cytogenetic feature
of cancer, relatively little was known about its biological relevance. DM chromosomes have a predisposition to involve
cancer oncogenes such as MYC proto-oncogene protein
(MYC), MDM2 proto-oncogene (MDM2) or cyclin-dependent kinase 4 (CDK4) [53, 113, 156, 186, 247]. A unique
feature of DM is that they lack centromeres and telomeres to
dictate the organization of the mitotic spindle during mitosis and are, therefore, randomly distributed across daughter
cells [103]. Interestingly, this feature hypothetically provides
DM chromosomes with an impressive fitness advantage over
linear chromosomes as they do not need telomeres to protect
them from inadvertent DNA damage response pathways and
are not subjected to detrimental BFB cycles. It has been
proposed that DM chromosomes are the result of the fusion
and circular assembly of stretches of linear DNA consisting
of highly homologous sequences of inverted duplications
in tandem following sequential BFB cycles (Fig. 3b) [205].
Others have proposed that ineffective DNA repair following
chromothripsis can lead to linear DNA fragments getting
pieced together in a circular fashion (Fig. 3c) [66]. A study
by our group found evidence of chromothripsis in several
glioblastoma samples localized to chromosome 12 involving MDM2 and CDK4 and suggested that these segments
may be arranged in extrachromosomal DMs [247]. Because
these are inherently random processes, it is possible that DM
chromosomes that promote survival are positively selected
for during telomere dysfunction. Compared to IDH-mutant
gliomas, DMs in IDH-wildtype tumors more often involve
established glioma oncogenes, despite what appears to be
a comparable frequency of DMs in both glioma categories
[57]. More research is needed to precisely determine the
frequency of DMs in glioma subtypes and to pinpoint the
genetic origin of these structures.
A recent study of paired primary and recurrent IDHmutant gliomas reported that in some cases allelic imbalances of the IDH-mutant allele occurred upon recurrence,
which led to a change in mutant protein expression and consequently decreased 2HG production [145]. Furthermore,
IDH-mutant tumors are very hard to culture, and when it
succeeds, IDH mutations that were present initially have
been reported missing, raising the possibility that losing
an IDH mutation is advantageous for survival in culture
[135]. Introduction of mutant IDH in cell cycle checkpointdeficient cells rapidly transforms these cells into competent
tumor cells [99]. However, IDH inhibition in these cells after
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as little as 4 days after its first introduction did little to slow
tumor growth. These findings suggest that some IDH-mutant
gliomas may rapidly evolve and acquire additional driver
events to uphold the tumor cell population.
To summarize, telomere dysfunction and stressed
growth may promote the context-dependent evolution of
glioma cells, sometimes rendering glioma initiation events
redundant and providing gliomas with new fuel that rapidly
increase intratumoral heterogeneity and can deal with various toxic stresses and bottlenecks. While stochastic mutational mechanisms in the stressed growth phase provide
ample selection pressure to acquire beneficial changes, the
detrimental genomic instability under which cells must operate acts as a powerful tumor suppressive barrier. Unchecked
growth will rapidly lead to another round of DNA damageinduced replicative senescence, or when those checkpoints
fail completely, cell crisis.

Phase IV: replicative senescence/crisis
Sustained stressed growth is not durable and will eventually lead tumor cells down to one of two possible roads.
Tumor cells with a partially intact senescence response
(i.e., functional p53 and RB) may undergo a second round
of senescence called replicative senescence in response to
dysfunctional telomeres. Tumor cells with a completely
dysfunctional senescence response (i.e., loss-of-function
mutation in TP53 or RB1) instead continue proliferating in
a state of cellular crisis leading to cell death in a vast majority of cells [51]. Replicative senescence and crisis both pose
a second population bottleneck to further tumor formation.
It is essential that tumor cells transition to a less stressful
environment with proper telomere maintenance to prevent
further BFB cycles and other catastrophic events. Cell
culture experiments have demonstrated that direct immortalization of cells prior to a stressed growth phase enables
them to bypass genomic instability and immortalize lacking the wild karyotypes typically associated with malignant
transformation [68, 154]. These observations suggest that
genomic instability in cancer development generally precedes immortal growth and is required to generate errors
enabling telomere maintenance [68].
Acquisition of a telomere maintenance mechanism
endows cancer cells with immortal growth, meaning that
they are bestowed a limitless replicative potential [108].
Telomere maintenance is established once a tumor cell has
reactivated telomerase or activated alternative lengthening
of telomeres. Moreover, restoration of telomere function
may prevent further BFB cycles and restore genome stability. The canonical pathway involves the reactivation of
the ribonucleoprotein telomerase which is transcriptionally
silent in differentiated adult cells [74]. The telomerase catalytic component telomerase reverse transcriptase (TERT) is
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expressed in over 80% of human cancers and is thought to be
rate limiting for telomerase activity [194]. In the alternative
pathway tumors become immortalized via a recombinationdriven mechanism called alternative lengthening of telomeres (ALT) [21].
IDH‑mutant diffuse astrocytomas
IDH-mutant diffuse astrocytomas almost universally demonstrate ALT [85]. ALT cells present with several defining characteristics, including a heterogeneous distribution
of telomere length across chromosomes, extrachromosomal telomeric DNA fragments in a circular configuration (c-circles), increased expression of telomeric repeatcontaining RNA (TERRA) from telomeres, the formation
of ALT-associated promyelocytic leukemia bodies (APBs),
frequent telomere sister chromatid exchanges (T-SCEs) and
recombination between telomeres from different chromosomes [58]. Telomeres in ALT cells are heterogeneous in
length and relatively long, demonstrating telomere lengths
much longer than telomerase-positive cells on average [22].
ALT provides cancer cells with stabilizing telomere maintenance in a telomerase-negative setting. Although it remains
unclear how ALT becomes activated, its presence has been
tightly associated with loss-of-function events targeting the
α-thalassemia/mental retardation syndrome X-linked (ATRX)
or death-domain-associated protein (DAXX) genes and these
events are also a hallmark feature of IDH-mutant astrocytomas [84, 98, 104]. ATRX functions as an ATP-dependent
helicase within the SWI/SNF family and combined these two
genes form the ATRX–DAXX complex, which functions
as a histone chaperone to deposit the histone variant H3.3
at telomeres [71]. Telomeric DNA has a tendency to form
secondary quadruplex structures that challenge the replication machinery and need to be resolved for proper replication [170]. How exactly these two genes protect telomeres
from recombination and ALT is still unknown. It has been
suggested that the combined helicase activity of ATRX and
the histone chaperone capabilities of the ATRX–DAXX
complex can resolve the secondary quadruplex structure at
telomeres, thereby enabling proper progression of the replication fork during S-phase and preventing the inadvertent
activation of recombination (ALT) mechanisms [121, 122].
The presence or absence of inactivating ATRX and DAXX
mutations present a strong correlation with ALT in many
tumor types including gliomas [84, 133, 191]. Recent
in vitro studies have shown that knockout of ATRX alone is
insufficient to cause ALT; however, ATRX knockout combined with inactivation of p53 and RB enzymatic activity
led to an increased incidence of ALT after enduring several cycles of telomere induced crisis [40, 155, 180]. Furthermore, the reintroduction of ATRX expression in ATRX
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mutant ALT cells led to a repression of T-SCE, APBs and
c-circle formation [40, 155].
IDH‑mutant oligodendrogliomas, 1p/19q‑codeleted
Oligodendrogliomas, IDH-mutant and 1p/19q-codeleted
almost universally use telomerase to maintain telomeres
and virtually all of these tumors carry an activating TERT
promoter mutation [106]. These TERT promoter mutations
are amongst the most common non-coding mutations in
cancer [89, 91, 106, 223]. Recurrent hotspot point mutations substitute a cytosine at − 228 or − 250 relative to the
promoter to a thymine (C228 > T or C250 > T) to create a de
novo e-twenty-six (ETS) transcription factor binding site that
recruits the ETS family member GA-binding protein alpha
chain (GABPA) to activate transcription [13].
Although the timing of TERT promoter mutations is still
under debate, several lines of evidence suggest that TERT
promoter mutations arise early in gliomagenesis and perhaps even occur prior to the glioma initiation event. TERT
promoter mutations preferentially occur in tissues with a
lower rate of self-renewal and there are numerous reports on
the extra-telomeric functions of TERT, including effects on
the NF-κB and WNT/β-catenin pathway promoting tumor
growth and invasiveness [106, 141, 169]. Combined, this
raises the possibility that these mutations may contribute to
tumorigenesis via other pathways than its effect on telomerase alone, providing a biological reason for these mutations
to contribute to gliomagenesis early in phase I and before
the onset of dysfunctional telomeres. In a glioma-specific
analysis, it was found that nearly all tumors with the ‘phase
I event’ + 7/− 10 or ‘phase II event’ 1p/19q-codeletion have
TERT promoter mutations, whereas not all TERT promoter
mutant gliomas have + 7/− 10 or 1p/19q-codeletions, which
may indicate that TERT promoter mutations even precede
+ 7/− 10 and 1p/19q-codeletions [34]. Another group studied the mutation fraction using multisector sequencing in
1p/19q-codeleted oligodendrogliomas and found that TERT
promoter mutations indeed are early events and may occur
before IDH mutations [204]. The idea that TERT promoter
mutation occurs early is further corroborated by the finding
that genetically engineered TERT promoter mutations in telomerase-positive embryonic stem cells do not affect telomerase activity, while upon differentiation these engineered cells
remain telomerase positive and acquire immortality [36].
More recently, it was found that TERT promoter mutations in
melanoma initially do not support telomere maintenance and
telomeres shorten to critically short length despite harboring
promoter mutations [37]. The effect on telomere length was
not observed until later, which the authors attributed to a
two-step immortalization process. One study even reported
canonical (− 228 and − 250) somatic TERT promoter mutations in the blood of multiple non-cancer patients, indicating
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that these events could even occur before the onset of cancer
and act to prime the tumor bed [143]. Although roles for
TERT outside of telomere maintenance remain to be understood, these observations provide a sound argument that
TERT promoter mutations can occur early in or even before
gliomagenesis while providing a means towards immortalization at a later stage.
IDH‑wildtype diffuse astrocytomas
The majority of IDH-wildtype diffuse gliomas use telomerase for telomere maintenance [120]. Re-analysis of previously published samples reclassified according to WHO
2016 criteria demonstrated that approximately 75% of diffuse IDH-wildtype gliomas are TERT promoter mutant
[172]. Thus, TERT promoter mutations are common in
both the most and the least aggressive diffuse gliomas
(IDH-wildtype diffuse astrocytomas and IDH-mutant and
1p19q-codeleted oligodendrogliomas, respectively), suggesting that TERT promoter mutations are not dictating
their biological behavior. It was further found that ATRX
mutations occur in approximately 5% of IDH-wildtype diffuse astrocytomas [172]. The prevalence of ALT in IDHwildtype diffuse gliomas is higher than the frequency of
ATRX mutations, suggesting that some of these tumors may
use ATRX-independent mechanisms to activate ALT [85].
In a similar fashion, the prevalence of telomerase activity is
higher than the prevalence of TERT promoter mutations in
this tumor type, suggesting that these tumors may use TERT
promoter-independent mechanisms for the reactivation of
telomerase [120]. Several candidate mechanisms have been
previously described in glioma, including TERT promoter
methylation or TERT amplifications [11]. Contrary to adult
IDH-wildtype diffuse glioma, H3-mutant malignant pediatric glioma frequently demonstrates ALT [140], and several
studies reported frequent co-occurrence of ATRX mutations
in both H3 K27 and G34 mutant gliomas. However, reports
of co-occurrence vary between 30 and 60% for K27 and
75–100% for G34, suggesting that there is a role for telomerase in many of these tumors as well [123].

Phase V: immortalization and dedifferentiation
The glioma stem cell theory states that amongst all cancerous cells in a tumor, a subset of cells act as progenitor or
stem cells with reproductive capabilities and sustaining
the cancer, much like normal bone marrow stem cells are
responsible for replenishing the population of circulating
leukocytes [221]. It has often been contrasted to the theory
of clonal evolution, which suggests that cancers evolve
through an iterative process of clonal expansion from a
single cell [73]. Recent advances in single-cell sequencing and lineage tracing have unveiled multiple populations
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of tumor cells in bulk tumor samples, providing fuel for
the cancer stem cell hypothesis [119, 171, 210, 219]. One
study used single-cell RNA sequencing on IDH-mutant
and 1p/19q-codeleted oligodendroglioma patient samples
and uncovered distinct cell populations of undifferentiated tumor stem cells and cells that are more differentiated
along various glial lineages [210]. In a similar study of
IDH-mutant astrocytoma the authors were able to detect
the same cellular populations but with a higher ratio of
stem-like to differentiated cells that increased with increasing WHO grades [219]. Another study used DNA barcoding of repeatedly in vivo-transplanted glioblastoma cells
to trace the lineage during their engraftment and found
a population of progenitor cells that sustained the tumor
and gave rise to differentiated non-proliferative cells [119].
These studies all provide support for a cancer stem cell
hypothesis and raise the question how these findings fit
with our model, which leans towards a model of clonal
evolution. In fact, current evidence may suggest that both
mechanisms are acting together (Fig. 4a). Whereas clonal
evolution is important to establish the initial cancer stem
cell population, neutral evolution (in line with the cancerstem cell hypothesis) may fit better once the initial cancer core has been established, especially so when further
evolutionary stimuli (e.g., senescence barriers, hypoxia,
treatment) are lacking. The concept of neutral evolution
holds that most molecular changes are not caused by natural selection but rather by the stochastic allelic variation
that are neutral and do not affect cellular fitness [109]. A
recent study analyzed cancer genomes from TCGA and
found neutral evolution in approximately one-third of a
wide spectrum of over 900 tumors, including 35 gliomas
of which 8 (23%) suggested evidence in support of a neutral evolution process [236]. The authors conclude that
all clonal selection must have occurred before the onset
of cancer growth and not in later arising subclones. Several groups have since challenged these findings and suggested that their analysis does not univocally prove neutral
evolution starting from the first malignant cell [157, 207,
237]. While it may be possible that tumors evolve neutrally beyond the most recent selective sweep we do not
agree with the conclusion that these findings suggest that
all clonal selection must occur before the onset of tumor
growth. The authors do not take into account that at the
time the tumor presents itself and is surgically removed,
all remnants of a selection process that have been outcompeted or died will have completely disappeared, in contrast
to “neutral” variants which do not affect fitness and will
remain. According to our simplified model, tumorigenesis
sequentially follows phase I–V. Once the cancer stem cell
population has been established, tumor cells will follow
neutral evolution, as long as new evolutionary or other
stimuli for opportunistic growth are lacking (Fig. 4a).
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Fig. 4  a Integration of a clonal
evolution and cancer stem cell
model for gliomagenesis. This
model assumes that sequential mutations and selection
pressure drive the evolution of
cancer stem-like cells. At the
same time, these stem-like cells
may give rise to more differentiated (i.e., phase IV) offspring
that may divide further but
rapidly become growth arrested.
b According to this model these
cells may be senescent and contribute to the cancer phenotype
by eliciting a microenvironment response via SASP. SASP
senescence-associated secretory
phenotype; ILs interleukins;
CXCLs chemokines (C–X–C
motif); CCLs chemokines (C–C
motif)

Aforementioned studies supporting the cancer stem cell
hypothesis suggest that multiple cellular populations exist
within a tumor, including a self-renewing cancer stem cell
population and a less-proliferative differentiated population.
A recent paper demonstrated that cells derived from glioma stem cells may differentiate and subsequently undergo
senescence [167]. We speculate that phase V tumor cells
represent cancer stem cells that may give rise to more differentiated, phase IV cells (Fig. 4a). The transition from phase
IV to V and vice versa is likely volatile in nature owing
to transcriptional reprogramming including the activation
of the stemness factors oligodendrocyte transcription factor 2 (OLIG2), sex-determining region Y-box 2 (SOX2) and
the reactivation of telomerase [203]. On the other hand, the
transition from phase I to phase IV is more rigid in nature,
involving various changes on a genomic level, including
somatic mutations and copy number changes as described.
This important distinction in flexibility led us to believe that
phase V cells may re-differentiate and assume a phase IV
state.
Although they are growth arrested, senescent cells are
metabolically active and release a plethora of signaling molecules to the microenvironment. The senescence-associated
secretory phenotype (SASP) is a feature of senescent cells
that curtails these cells with the release of proinflammatory
cytokines [47]. SASP does not depend on p16INK4a or p21
activity and senescence with intact p 16INKa function actually
suppresses SASP [49]. Similarly, activated p53 signaling
also suppresses SASP while TP53 loss induces SASP [48,
136, 178]. These findings suggest that the SASP response is
stronger when senescence pathway genes are lost. Indeed,
IDH-wildtype astrocytomas often harbor homozygous

deletions in CDKN2A/B and are known to have a highly
active microenvironment [230]. Genes associated with SASP
were shown to be overexpressed in higher grades of glioma
and older patients, the latter group more likely to be affected
by high-grade IDH-wildtype astrocytoma [50]. Moreover,
it was found that primary glioblastoma cells retain a functional senescence program despite mutations in the TERT
promoter and CDKN2A/B locus [118]. These findings imply
that senescent and differentiated phase IV cells may be crucial for shaping the immune microenvironment in gliomas
(Fig. 4b).

A broader perspective
While there are not many known environmental risk factors that predispose to glioma, large cohort genome-wide
association studies over the past two decades have identified multiple heritable polymorphisms conferring glioma
risk [96, 110, 152, 179, 196, 238]. Notably, several of these
risk loci are localized to genes involved in telomere maintenance, including the telomerase reverse transcriptase TERT,
telomerase RNA component TERC, and other telomere
maintenance-associated genes STN1, CST complex subunit
(OBFC1), protection of telomeres 1 (POT1) and regulator
of telomere elongation 1 (RTEL1) [152]. Moreover, there
appears to be a significant increased glioma risk in people
with increased leukocyte telomere lengths [45]. Unsurprisingly, glioma risk alleles at aforementioned genes are also
associated with increased leukocyte telomere length [41,
226, 228]. Telomeres thus play an important role in not only
the development of gliomas, but also in glioma risk [227].
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In fact, the positive association between leukocyte telomere
length and cancer risk is not specific to glioma and shared
across many cancers. A recent Mendelian randomization
study found that longer leukocyte telomere length was associated with an increased risk to cancer but a reduced risk to
non-neoplastic disease such as cardiovascular disease [209].
It has been suggested that this difference is due to individuals with longer telomeres being more likely to acquire driver
mutations due to an increased proliferative potential whereas
the inverse relationship observed for non-neoplastic disease
may be due to the impact of telomere shortening on tissue
degeneration [19, 200].
Several hereditary disorders are associated with an
increased risk of glioma development, including neurofibromatosis type 1 and type 2 (NF1, NF2) and the TP53
germline mutation/Li–Fraumeni syndrome. NF1 and NF2
are autosomal dominant hereditary disorders with germline
mutations in NF1 and NF2 and clinically characterized by
multiple benign nerve sheath tumors (especially neurofibromas in NF1, schwannomas in NF2), but also by a markedly
increased risk on particular gliomas (especially pilocytic
astrocytoma in NF1 and ependymomas in NF2) [33, 76,
184]. Both genes are well-known tumor suppressor genes
and key components in the MAPK pathway [38]. It has been
demonstrated that senescence commonly occurs in benign
nerve sheath tumors and that prolonged NF1 disruption
leads to oncogene-induced senescence in a model system,
providing a rationale as to why these germline disorders present with tumors that are often relatively indolent [52]. A
germline perturbation affecting NF1 or NF2 can be considered a tumor initiation event, explaining why this germline
disorder guarantees the formation of multiple benign nerve
sheath tumors over one’s lifetime.
Li–Fraumeni syndrome is a rare autosomal dominant
hereditary disorder that is caused by the germline perturbation of TP53 or CHK2, which regulates p53 activity [12,
18, 146]. Whereas NF1 and NF2 guarantee the formation of
especially multiple benign tumors (including non-diffuse gliomas) in a lifetime, Li–Fraumeni patients pose a greater risk
to developing a malignant tumor, including a diffuse glioma
[17]. This risk increases with age and is over 50% at age 30,
with a lifetime cancer risk of over 70% in men and almost
100% in women [146]. Moreover, 15 and 4% of affected
individuals were found to develop a second and third cancer [86]. Li–Fraumeni syndrome germline mutations affect
phase II and prevent the onset of oncogene-induced senescence following the acquisition of a glioma initiation event,
thus increasing the risk of developing cancer over a lifetime.
The germline mutations underlying NF1/NF2 and
Li–Fraumeni syndrome represent pathways that both need
to be disrupted for a malignant tumor to form. The fact
that nearly all patients with NF1/NF2 develop one or more
benign tumors can be understood by acknowledging that in
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these disorders a germline tumor initiation event is involved.
Unless this pathway is supplemented by a senescence bypass
event, these tumors do not readily proceed to malignancy.
In contrast, Li–Fraumeni syndrome is characterized by an
increased risk for malignant tumors in many (but not all)
patients. In this syndrome, the germline senescence bypass
event needs to be supplemented by a tumor initiation event
for a tumor to develop, and such tumors may be more
aggressive/malignant due to the defective senescence barrier, allowing the tumor (precursor) cell to instantly progress
to phase III and instigate genomic instability.

Conclusion
Our knowledge on the molecular events driving cancer has
grown exponentially over the years. This review has aimed
to put this new knowledge into the perspective of the temporal molecular pathogenesis of glioma, starting from the
first aberrant cell all the way to a symptom-causing glioma.
To this end we have combined what is known on gene (mal)
function, tumor evolution, genomic instability and telomere
maintenance to develop a model of gliomagenesis. This
model describes five sequential phases cancer cells undergo
during their gliomagenesis. We speculate that transitions
from one phase to the next can be characterized by acquisition of tumor-driving events that sequentially contribute to
the hallmarks of cancer as previously proposed, including
proliferation, evasion of apoptosis and limitless replicative
potential [79, 80]. Our model is a simplified abstraction
of what may be the truth and new insights will refine and
improve our understanding. Meanwhile, we hope that our
model will help foster hypotheses leading to new insights
into the molecular life history of glioma that will help identify convincing therapeutic vulnerabilities.
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